Long-Term Safety and Efficacy of Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE/ADHERE+ Trial Interim Analysis.
J Peripher Nerv SystSep 1, 2026
Jeffrey A Allen, Geoffrey Istas, Satoshi Kuwabara et al.
✦ AI-curated · Sources linked
In 30 seconds
The ADHERE/ADHERE+ trial evaluated the long-term safety and efficacy of efgartigimod PH20 in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). This multicenter randomized controlled trial found that prolonged exposure to efgartigimod was well tolerated, with 75.0% of participants experiencing treatment-emergent adverse events (TEAEs) and significant improvements in disability and grip strength over 36 weeks.
Key findings
- 75.0% of participants experienced treatment-emergent adverse events, with 18.0% being grade ≥3.
- Mean aINCAT score decreased by 1.2 points, indicating improved disability.
- I-RODS centile metric increased by 8.8 points, reflecting enhanced overall function.
- Mean grip strength improved by 17.5 kPa from baseline to week 36.
Why it matters
The findings suggest that efgartigimod PH20 may provide a safe and effective long-term treatment option for patients with CIDP, potentially improving their quality of life through enhanced functional outcomes.